Key facts
- Sensip-dx’s last known valuation is $4.6M (Mar 2026).
- It has raised $2.2M; the latest was Seed Round ($4.3M) in Mar 2026.
- Notable investors include StartLife, Maastricht University, ScaleNL.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Sensip-dx
- ·The full record, as it builds
Funding rounds
No funding rounds for Sensip-dx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sensip-dx
Developer of a rapid diagnostic device designed to detect and quantify living bacteria onsite, reducing the wait time for test results. The company offers a 15-minute testing platform with single-use cartridges, cost competitiveness, and proprietary patents, enabling food safety laboratories and manufacturers faster and more accurate pathogen detection.
- Sector
- Information Technology
- HQ
- Maastricht, Netherlands
- Founded
- 2020
- Employees
- 7
- Website
- sensipdx.com/
- Ownership
- Privately Held (backing)
Sensip-dx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sensip-dx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sensip-dx in its N-PORT filings yet. We sweep new filings monthly.